Liquidia Stock (NASDAQ:LQDA)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$38.86

52W Range

$21.94 - $93.61

50D Avg

$56.54

200D Avg

$54.03

Market Cap

$3.55B

Avg Vol (3M)

$3.19M

Beta

0.54

Div Yield

-

LQDA Company Profile

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

216

IPO Date

Jul 26, 2018

Website

LQDA Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 20
Product	$148.29M	-
Service	$10.03M	-
Promotion Agreement	-	$739.63K
Research and Development Services	-	-

Fiscal year ends in Dec 25 | Currency in USD

LQDA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$158.32M	$14.00M	$17.49M
Operating Income	$-51.38M	$-121.29M	$-73.38M
Net Income	$-68.92M	$-130.39M	$-78.50M
EBITDA	$-51.38M	$-115.71M	$-70.05M
Basic EPS	$-0.80	$-1.66	$-1.21
Diluted EPS	$-0.80	$-1.66	$-1.21

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Aug 12, 26 | 8:30 AM

Q1 26May 11, 26 | 8:30 AM

Q4 25Mar 05, 26 | 8:30 AM

Peer Comparison

Ticker	Company
UTHR	United Therapeutics Corporation
VCRE	Vicore Pharma Holding AB
INSM	Insmed Incorporated
AVLN	Avalyn Pharma Inc. Common Stock